GLP1R and atherosclerosis: Vinué et al. demonstrated that the GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant Apoe−/−Irs2+/− mice by promoting macrophage polarization towards an anti-inflammatory M2 phenotype, which was associated with enhanced plaque stability (i.e., thicker fibrous caps, fewer necrotic cores, and decreased inflammatory infiltrates).